LindaG.P.SchneiderMDMBA, FAAFP

Clinical Trials

• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial Start of enrollment: 2022 Dec 14

  Active, not recruiting

  Phase 3

• A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Start of enrollment: 2023 Sep 27

  Recruiting

  Phase 3

• A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia Start of enrollment: 2021 Sep 30

  Terminated

  Phase 3

• Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome Start of enrollment: 2021 Jun 24

  Active, not recruiting

  Phase 3

• Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) Start of enrollment: 2021 Apr 28

  Completed

  Phase 2

• Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) Start of enrollment: 2023 Nov 07

  Recruiting

  Phase 3

• A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Start of enrollment: 2022 Nov 01

  Active, not recruiting

  Phase 3

• EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) Start of enrollment: 2020 Dec 16

  Completed

  Phase 3

• A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes. Start of enrollment: 2022 Apr 20

  Completed

  Phase 1

• A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism Start of enrollment: 2022 Apr 29

  Active, not recruiting

  Phase 2

• EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 Start of enrollment: 2021 Jul 16

  Completed

  Phase 2, Phase 3

• Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). Start of enrollment: 2021 Aug 25

  Terminated

  Phase 2, Phase 3

• A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Start of enrollment: 2021 Sep 09

  Completed

  Phase 2, Phase 3

• Join now to see all